Skip to content

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-000458-72-FI
Enrollment
30
Registered
2012-02-24
Start date
2012-05-25
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery by-pass surgery patients MedDRA version: 14.1 Level: LLT Classification code 10011076 Term: Coronary artery atherosclerosis System Organ Class: 10007541 - Cardiac disorders

Interventions

Trade Name: Metoprolin Product Name: Metoprolin Product Code: 10456 Pharmaceutical Form: Tablet CAS Number: 125-04-2 Other descriptive name: HYDROCORTISONE SODIUM SUCCINATE Trade Name: Solu-Cortef Pr

Sponsors

Juha Hartikainen
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 10

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Primary end point(s): concentration of metoprolol in plasma after dosage of the drug, difference between study and placebo group;Timepoint(s) of evaluation of this end point: metoprolol level in plasma 4, 6, 8, and 12 hours after administration, same protocol 4 days postoperatively;Main Objective: Patients;Secondary Objective: None

Secondary

MeasureTime frame
Timepoint(s) of evaluation of this end point: none

Countries

Finland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026